Compare Dr. Reddys with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs PANACEA BIOTECH - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB PANACEA BIOTECH DR. REDDYS LAB/
PANACEA BIOTECH
 
P/E (TTM) x 21.5 11.4 189.1% View Chart
P/BV x 3.2 2.7 117.8% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 DR. REDDYS LAB   PANACEA BIOTECH
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-19
PANACEA BIOTECH
Mar-18
DR. REDDYS LAB/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs2,875364 789.8%   
Low Rs1,888129 1,462.4%   
Sales per share (Unadj.) Rs930.296.8 961.2%  
Earnings per share (Unadj.) Rs117.4-12.4 -946.3%  
Cash flow per share (Unadj.) Rs185.8-2.9 -6,512.5%  
Dividends per share (Unadj.) Rs20.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs844.450.4 1,675.5%  
Shares outstanding (eoy) m166.0761.25 271.1%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.62.5 100.5%   
Avg P/E ratio x20.3-19.9 -102.1%  
P/CF ratio (eoy) x12.8-86.4 -14.8%  
Price / Book Value ratio x2.84.9 57.6%  
Dividend payout %17.00-   
Avg Mkt Cap Rs m395,49615,101 2,619.0%   
No. of employees `00022.02.5 890.0%   
Total wages/salary Rs m33,5621,516 2,214.0%   
Avg. sales/employee Rs Th7,032.82,401.9 292.8%   
Avg. wages/employee Rs Th1,527.9614.2 248.8%   
Avg. net profit/employee Rs Th887.7-307.9 -288.3%   
INCOME DATA
Net Sales Rs m154,4825,928 2,606.0%  
Other income Rs m3,37582 4,100.9%   
Total revenues Rs m157,8576,010 2,626.5%   
Gross profit Rs m31,782845 3,759.8%  
Depreciation Rs m11,348585 1,938.8%   
Interest Rs m8891,006 88.4%   
Profit before tax Rs m22,920-664 -3,454.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m4382 20,857.1%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,85899 3,912.8%   
Profit after tax Rs m19,500-760 -2,565.8%  
Gross profit margin %20.614.3 144.3%  
Effective tax rate %16.8-14.9 -113.3%   
Net profit margin %12.6-12.8 -98.5%  
BALANCE SHEET DATA
Current assets Rs m111,1015,603 1,982.7%   
Current liabilities Rs m58,9736,910 853.4%   
Net working cap to sales %33.7-22.0 -153.1%  
Current ratio x1.90.8 232.3%  
Inventory Days Days79206 38.6%  
Debtors Days Days9484 112.5%  
Net fixed assets Rs m101,2459,941 1,018.5%   
Share capital Rs m83061 1,354.0%   
"Free" reserves Rs m139,4063,026 4,607.5%   
Net worth Rs m140,2363,087 4,542.9%   
Long term debt Rs m22,0005,707 385.5%   
Total assets Rs m224,65616,076 1,397.5%  
Interest coverage x26.80.3 7,869.4%   
Debt to equity ratio x0.21.8 8.5%  
Sales to assets ratio x0.70.4 186.5%   
Return on assets %9.11.5 593.6%  
Return on equity %13.9-24.6 -56.5%  
Return on capital %14.93.9 381.6%  
Exports to sales %024.0 0.0%   
Imports to sales %017.5 0.0%   
Exports (fob) Rs mNA1,424 0.0%   
Imports (cif) Rs mNA1,040 0.0%   
Fx inflow Rs m88,6731,600 5,542.0%   
Fx outflow Rs m19,1041,131 1,688.5%   
Net fx Rs m69,569469 14,846.5%   
CASH FLOW
From Operations Rs m28,7041,180 2,432.1%  
From Investments Rs m-7,727553 -1,397.5%  
From Financial Activity Rs m-21,326-1,644 1,297.6%  
Net Cashflow Rs m-31490 -350.1%  

Share Holding

Indian Promoters % 25.5 74.5 34.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 0.6 900.0%  
FIIs % 35.3 1.3 2,715.4%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 23.6 64.8%  
Shareholders   75,885 10,259 739.7%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   NATCO PHARMA  PLETHICO PHARMA  GLENMARK PHARMA  TORRENT PHARMA  FRESENIUS KABI ONCO.  

Compare DR. REDDYS LAB With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends above 39,000-Mark; Automobile and Banking Stocks Witness Buying(Closing)

Extending gains to the fifth day, Indian share markets rose sharply during the afternoon session and ended on a strong note.

Related Views on News

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

PANACEA BIOTECH Announces Quarterly Results (2QFY19); Net Profit Down 1631.6% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, PANACEA BIOTECH has posted a net profit of Rs 975 m (down 1631.6% YoY). Sales on the other hand came in at Rs 1 bn (down 22.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Oct 17, 2019 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 8-QTR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS